Table 2.
MDS-UPDRS scores between baseline and 12 months.
| Baseline | 3 months | 6 months | 12 months | Change |
p value | |
|---|---|---|---|---|---|---|
| (0–12 months) | ||||||
| MDS-UPDRS part 3 (off-medication) | ||||||
| Donor FMT | 40.3 (2.7) | 38.3 (2.7) | 38.8 (2.6) | 34.6 (3.0) | −5.8 (2.0) | 0.0235 |
| Placebo FMT | 37.1 (2.5) | 32.6 (2.6) | 31.5 (2.5) | 34.5 (2.9) | −2.7 (1.9) | |
| MDS-UPDRS part 1 | ||||||
| Donor FMT | 11.0 (1.3) | 11.1 (1.4) | 10.6 (1.4) | 11.0 (1.3) | 0.1 (0.9) | 0.7875 |
| Placebo FMT | 10.6 (1.3) | 9.9 (1.4) | 8.4 (1.4) | 9.3 (1.2) | −1.3 (0.9) | |
| MDS-UPDRS part 2 | ||||||
| Donor FMT | 10.7 (1.3) | 11.2 (1.3) | 12.0 (1.4) | 12.1 (1.3) | 1.4 (0.8) | 0.7059 |
| Placebo FMT | 8.0 (1.2) | 8.3 (1.3) | 8.8 (1.3) | 8.5 (1.3) | 0.6 (0.8) | |
| MDS-UPDRS part 4 | ||||||
| Donor FMT | 2.2 (0.6) | 2.3 (0.5) | 2.1 (0.6) | 2.4 (0.6) | 0.2 (0.4) | 0.6308 |
| Placebo FMT | 2.6 (0.5) | 2.5 (0.5) | 2.8 (0.6) | 2.5 (0.6) | −0.1 (0.4) | |
| MDS-UPDRS total | ||||||
| Donor FMT | 63.9 (4.2) | 62.7 (4.3) | 62.7 (4.4) | 60.1 (4.6) | −3.7 (2.8) | 0.2884 |
| Placebo FMT | 58.2 (4.0) | 53.3 (4.1) | 51.2 (4.2) | 54.9 (4.5) | −3.3 (2.8) | |
Data are mean (SEM). MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale. Significant differences (p < 0.05) are indicated in bold.